Targeted Therapies for Prostate Cancer

被引：7

作者：

Petrioli, Roberto ^{[1
]}

Francini, Edoardo ^{[2
]}

Fiaschi, Anna Ida ^{[3
]}

Laera, Letizia ^{[1
]}

Roviello, Giandomenico ^{[1
]}

机构：

[1] Univ Siena, Med Oncol Unit, I-53100 Siena, Italy

[2] Univ Rome, Med Oncol Unit, Policlin Umberto I Hosp, Rome, Italy

[3] Univ Siena, Pharmacol Unit, I-53100 Siena, Italy

来源：

CANCER INVESTIGATION | 2015年 / 33卷 / 07期

关键词：

Prostate cancer; Biologic agents; Target therapy; Docetaxel; RANDOMIZED PHASE-II; DOCETAXEL PLUS PREDNISONE; ENDOTHELIAL GROWTH-FACTOR; DOUBLE-BLIND; MEMBRANE ANTIGEN; ANTISENSE OLIGONUCLEOTIDE; MONOCLONAL-ANTIBODY; INCREASED SURVIVAL; CTLA-4; BLOCKADE; DOSE-ESCALATION;

D O I：

10.3109/07357907.2015.1033105

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

New therapies for prostate cancer have emerged over the past three years. Nevertheless, none of these agents is curative, and unfortunately, patients often ultimately develop resistance to these agents. Therefore, the development of innovative and effective therapies that overcome these resistances is necessary. Unfortunately, the results of a phase III trial evaluating docetaxel in combination with targeted therapies demonstrated no difference in survival. Moreover, scarce data on the combination of a targeted therapy with new agents are currently available. New trials are investigating these possible combination treatments; the results of these (on-going) clinical studies are awaited.

引用

页码：276 / 285

页数：10

共 84 条

[1]

Agarwal N, 2010, FUTURE ONCOL, V6, P665, DOI [10.2217/fon.10.48, 10.2217/FON.10.48]

[2] Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts [J].

Anai, Satoshi ;

Goodison, Steve ;

Shiverick, Kathleen ;

Hirao, Yoshihiko ;

Brown, Bob D. ;

Rosser, Charles J. .

MOLECULAR CANCER THERAPEUTICS, 2007, 6 (01) :101-111

[3]

[Anonymous], J CLIN ONCOL

[4]

[Anonymous], 2008, JCO

[5]

[Anonymous], J CLIN ONCOL S

[6] Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial [J].

Araujo, John C. ;

Trudel, Geralyn C. ;

Saad, Fred ;

Armstrong, Andrew J. ;

Yu, Evan Y. ;

Bellmunt, Joaquim ;

Wilding, George ;

McCaffrey, John ;

Serrano, Sergio V. ;

Matveev, Vsevolod B. ;

Efstathiou, Eleni ;

Oudard, Stephane ;

Morris, Michael J. ;

Sizer, Bruce ;

Goebell, Peter J. ;

Heidenreich, Axel ;

de Bono, Johann S. ;

Begbie, Stephen ;

Hong, Jun H. ;

Richardet, Eduardo ;

Gallardo, Enrique ;

Paliwal, Prashni ;

Durham, Susan ;

Cheng, Shinta ;

Logothetis, Christopher J. .

LANCET ONCOLOGY, 2013, 14 (13) :1307-1316

[7] Dasatinib combined with docetaxel for castration-resistant prostate cancer [J].

Araujo, John C. ;

Mathew, Paul ;

Armstrong, Andrew J. ;

Braud, Edward L. ;

Posadas, Edwin ;

Lonberg, Mathew ;

Gallick, Gary E. ;

Trudel, Geralyn C. ;

Paliwal, Prashni ;

Agrawal, Shruti ;

Logothetis, Christopher J. .

CANCER, 2012, 118 (01) :63-71

[8] A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer [J].

Armstrong, Andrew J. ;

Creel, Patricia ;

Turnbull, James ;

Moore, Cassandra ;

Jaffe, Tracy A. ;

Haley, Sherri ;

Petros, William ;

Yenser, Sarah ;

Gockerman, Jon P. ;

Sleep, Darryl ;

Hurwitz, Herbert ;

George, Daniel J. .

CLINICAL CANCER RESEARCH, 2008, 14 (19) :6270-6276

[9] The endothelin axis in cancer [J].

Bagnato, Anna ;

Rosano, Laura .

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2008, 40 (08) :1443-1451

[10] Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer [J].

Bander, NH ;

Milowsky, MI ;

Nanus, DM ;

Kostakoglu, L ;

Vallabhajosula, S ;

Goldsmith, SJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (21) :4591-4601

← 1 2 3 4 5 6 7 8 9 →